Qiming Venture Partners and Its Investors Named to 36Kr China Equity Investment Annual Lists
Time only rewards those who truly understand what they're doing.
启明创投
@author-1788515151757110
启明创投致力于成为中国优秀技术创业者们的首选投资机构
345 articles
Articles
Qiming Star | MedLinkTherapeutics' Xue Tongtong: In ADC's Blue Ocean Era, the Pragmatic Will Prevail
Yili Biotech Could Become the Next Big Pharma
Qiming Weekly | Top 10 News from Qiming Venture Partners' Portfolio Companies Vol.21, 2026.6.23
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners' William Hu: Healthcare Investment Isn't About Hot or Cold Sectors—It's About Whether There's Enough Disruptive Potential
Someday, as China's economic and innovative strength grows, the value of Chinese entrepreneurs will naturally be reassessed.
Qiming Weekly | Qiming Venture Partners Portfolio News: Top 10 Updates Vol.20, June 16, 2026
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Qiming View | William Hu: Globalization of China's Healthcare Innovation Just Beginning, Will Be Investment Theme for Next 10-20 Years
China's healthcare innovation globalization has only just begun, and it will remain a sustained investment theme for the next 10-20 years.
Qiming Headlines: Intelligence Ignites the Future — Qiming Venture Partners' 17th RMB Fund Annual Meeting and Investor Summit Successfully Held in Shanghai
Qiming Venture Partners Maintains Investment Discipline, Proactively Captures Market Opportunities as Deal Flow Continues
Qiming Venture Partners Weekly | Top 10 Portfolio Company Updates Vol.19, June 9, 2026
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Dongsheng Fusion Raises $100 Million in New Funding Round, Co-Led by Qiming Venture Partners
J&T Global Express is committed to developing strong magnetic field compact fusion power plant technology using "deuterium-helium-3" as fuel.
Qiming Venture Partners Portfolio Company Tiachen Biologics, a Leader in Allergy and Autoimmune Innovative Drugs in China, Successfully Lists on Hong Kong Exchanges and Clearing Limited
In 2024, Qiming Venture Partners led TianChen Bio's Series B2 round, and then co-led the company's Series C round in 2025.